Related Experiment Video

Updated: May 31, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

miR 488* inhibits androgen receptor expression in prostate carcinoma cells

Kavleen Sikand1, Jinani E Slaibi, Rajesh Singh

  • 1Center for Gene Regulation in Health and Disease, Cleveland State University, 2121 Euclid Avenue, Cleveland, OH, USA.

International Journal of Cancer
|June 29, 2011
PubMed

Insights

MicroRNAs, specifically miR 488*, can target the androgen receptor (AR) to inhibit prostate cancer (PCa) cell growth. This discovery offers a new therapeutic strategy for overcoming resistance to antiandrogen treatments in prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Androgen receptor (AR) signaling is crucial in prostate cancer (PCa) development and treatment.
  • Resistance to antiandrogen therapy often involves increased AR levels.
  • MicroRNAs (miRNAs) are emerging as tumor suppressors with therapeutic potential.

Purpose of the Study:

  • To investigate the role of miR 488* in regulating AR expression and activity in PCa.
  • To evaluate the therapeutic potential of miR 488* in both androgen-dependent and independent PCa cells.

Main Methods:

  • Overexpression of miR 488* in PCa cell lines.
  • Assessment of AR transcriptional activity and protein levels.
  • Evaluation of cell proliferation and apoptosis rates.

Main Results:

  • Overexpression of miR 488* significantly downregulated AR transcriptional activity.
  • miR 488* inhibited endogenous AR protein production in PCa cells.
  • miR 488* suppressed PCa cell proliferation and promoted apoptosis.

Conclusions:

  • miR 488* directly targets AR, modulating AR-mediated signaling pathways.
  • miR 488* demonstrates potential as a novel therapeutic agent to target AR in prostate cancer.
  • Targeting AR with miRNAs may offer a strategy to overcome antiandrogen resistance.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...